Original Articles
Vol. 1 No. 2 (2022)
Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 5 May 2022
Accepted: 1 June 2022
Accepted: 1 June 2022
1160
Views
257
Downloads
Authors
Circulating albumin and fibrinogen levels, commonly considered as inflammatory markers, have been shown to be associated with venous thromboembolism (VTE) risk. Circulating albumin-to-fibrinogen ratio (AFR) has been proposed as a novel inflammatory biomarker, but its association with VTE risk has not been investigated. We aimed to assess the prospective association of AFR with VTE risk. Circulating albumin and fibrinogen levels were measured at baseline in 2,284 men aged 42-61 years. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. During a median follow-up of 27.0 years, 156 VTE cases were recorded. In analysis adjusted for established risk factors, the HR (95% CI) for VTE comparing extreme tertiles of AFR was 1.53 (1.02-2.32), which remained similar on further adjustment for prevalent cancer, 1.52 (1.01-2.30). The associations of circulating albumin or fibrinogen with VTE risk were modest. Circulating AFR may be a stronger risk indicator for VTE compared with albumin or fibrinogen alone.
Downloads
Download data is not yet available.
Citations
Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2. DOI: https://doi.org/10.1161/ATVBAHA.108.162545
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-74. DOI: https://doi.org/10.1038/nrcardio.2015.83
Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62-9. DOI: https://doi.org/10.1053/j.seminhematol.2007.02.004
Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9. DOI: https://doi.org/10.1055/s-0037-1615887
Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005;94:362-5. DOI: https://doi.org/10.1160/TH05-04-0266
Kunutsor SK, Sameul S, Blom AW, et al. Serum C-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence Eur J Epidemiol 2017 32:657-67. DOI: https://doi.org/10.1007/s10654-017-0277-4
Kunutsor SK, Seidu S, Katechia DT, Laukkanen JA. Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein. Ann Med 2018:1-9. DOI: https://doi.org/10.1080/07853890.2018.1441537
Klovaite J, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med 2013;187:286-93. DOI: https://doi.org/10.1164/rccm.201207-1232OC
Chi G, Gibson CM, Liu Y, et al. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol 2019;94:21-8. DOI: https://doi.org/10.1002/ajh.25296
Lin C, Chen Y, Chen B, et al. D-Dimer Combined with Fibrinogen Predicts the Risk of Venous Thrombosis in Fracture Patients. Emerg Med Int 2020;2020:1930405. DOI: https://doi.org/10.1155/2020/1930405
Wang J, Xi H, Zhang K, et al. Circulating C-Reactive Protein to Prealbumin Ratio and Prealbumin to Fibrinogen Ratio are Two Promising Inflammatory Markers Associated with Disease Activity in Rheumatoid Arthritis. Clin Lab 2020;66. DOI: https://doi.org/10.7754/Clin.Lab.2019.190833
Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53. DOI: https://doi.org/10.1111/j.1365-2362.2009.02234.x
Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46-50.
Kunutsor SK, Khan H, Laukkanen JA. Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study. Diabetologia 2015;58:961-7. DOI: https://doi.org/10.1007/s00125-015-3520-0
Liu Z, Mi J. Serum Albumin and Circulating Metabolites and Risk of Venous Thromboembolism: A Two-Sample Mendelian Randomization Study. Front Nutr 2021;8:712600. DOI: https://doi.org/10.3389/fnut.2021.712600
Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010;104:100-4. DOI: https://doi.org/10.1160/TH09-12-0856
Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195-202. DOI: https://doi.org/10.1016/j.jclinepi.2003.07.001
Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16A:11-4. DOI: https://doi.org/10.1093/eurheartj/16.suppl_A.11
Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995;89:205-14. DOI: https://doi.org/10.1042/cs0890205
How to Cite
1.
Kunutsor SK, Kurl S, Voutilainen A, Laukkanen J. Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study. Bleeding Thromb Vascul Biol [Internet]. 2022 Jul. 14 [cited 2025 Nov. 8];1(2). Available from: https://www.btvb.org/btvb/article/view/36
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share
Similar Articles
- CS03 | Khorana risk score and genomic profiling for prediction of venous thromboembolism in ovarian cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia, Anticoagulation in obese patients: challenges and strategies , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Stefania Cavazza, Gualtiero Palareti*, Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Daniela Tormene, Elena Campello, Chiara Simion, Anna Poretto, Paolo Prandoni, Paolo Simioni, Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO10 | Multidimensional risk assessment of venous thromboembolism (risk): an observational study comparing the Padua prediction score, Barthel index, and quality of life in hospitalized patients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO35 | Cerebral veins thrombosis in patients with and without myeloproliferative neoplasm: a real life retrospective monocentric study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
1-10 of 195
Next
You may also start an advanced similarity search for this article.
